167 related articles for article (PubMed ID: 9874327)
21. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
22. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Young G; Shende A
Med Pediatr Oncol; 1998 Feb; 30(2):117-21. PubMed ID: 9403021
[TBL] [Abstract][Full Text] [Related]
23. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study.
Plotkin H; Coughlin S; Kreikemeier R; Heldt K; Bruzoni M; Lerner G
Dev Med Child Neurol; 2006 Sep; 48(9):709-12. PubMed ID: 16904014
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation.
Fan SL; Kumar S; Cunningham J
Kidney Int; 2003 Jun; 63(6):2275-9. PubMed ID: 12753318
[TBL] [Abstract][Full Text] [Related]
25. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
Williams CJ; Smith RA; Ball RJ; Wilkinson H
Arch Dis Child; 1997 Feb; 76(2):169-70. PubMed ID: 9068314
[TBL] [Abstract][Full Text] [Related]
26. Pamidronate-induced irreversible symptomatic hypocalcemia in a dog with hypercalcemia after glucocorticoid withdrawal: a case report.
Oh YI; An JH; Lim GH; Park SM; Kim TH; Seo KW; Youn HY
BMC Vet Res; 2024 May; 20(1):227. PubMed ID: 38790012
[TBL] [Abstract][Full Text] [Related]
27. Immobilization-related hypercalcemia after renal failure in burn injury.
Peralta MC; Gordon DL
Endocr Pract; 2002; 8(3):213-6. PubMed ID: 12113635
[TBL] [Abstract][Full Text] [Related]
28. Prevention of bone loss and fracture after lung transplantation: a pilot study.
Cahill BC; O'Rourke MK; Parker S; Stringham JC; Karwande SV; Knecht TP
Transplantation; 2001 Oct; 72(7):1251-5. PubMed ID: 11602851
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.
Acott PD; Wong JA; Lang BA; Crocker JF
Pediatr Nephrol; 2005 Mar; 20(3):368-73. PubMed ID: 15690187
[TBL] [Abstract][Full Text] [Related]
30. Immobilization hypercalcemia in incomplete paraplegia: successful treatment with pamidronate.
Kedlaya D; Brandstater ME; Lee JK
Arch Phys Med Rehabil; 1998 Feb; 79(2):222-5. PubMed ID: 9474008
[TBL] [Abstract][Full Text] [Related]
31. Osteopenia and fractures in cystinotic children post renal transplantation.
Zimakas PJ; Sharma AK; Rodd CJ
Pediatr Nephrol; 2003 Apr; 18(4):384-90. PubMed ID: 12700967
[TBL] [Abstract][Full Text] [Related]
32. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
Bone; 1990; 11(1):15-20. PubMed ID: 2331426
[TBL] [Abstract][Full Text] [Related]
33. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
34. Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Omidvar B; Ghorbani A; Shahbazian H; Beladi Mousavi SS; Shariat Nabavi SJ; Alasti M
Iran J Kidney Dis; 2011 Nov; 5(6):420-4. PubMed ID: 22057076
[TBL] [Abstract][Full Text] [Related]
35. Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates.
Auron A; Tal L; Srivastava T; Alon US
Pediatr Nephrol; 2009 Mar; 24(3):613-7. PubMed ID: 18839218
[TBL] [Abstract][Full Text] [Related]
36. Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
Howe W; Davis E; Valentine J
Dev Neurorehabil; 2010 Feb; 13(1):31-6. PubMed ID: 20067343
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass.
Valk NK; Erdtsieck RJ; Algra D; Lamberts SW; Pols HA
Clin Endocrinol (Oxf); 1995 Sep; 43(3):317-24. PubMed ID: 7586601
[TBL] [Abstract][Full Text] [Related]
38. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of acute administration of pamidronate on the conservation of bone mass following severe burn injury in children: a double-blind, randomized, controlled study.
Klein GL; Wimalawansa SJ; Kulkarni G; Sherrard DJ; Sanford AP; Herndon DN
Osteoporos Int; 2005 Jun; 16(6):631-5. PubMed ID: 15452689
[TBL] [Abstract][Full Text] [Related]
40. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
